北陆药业(300016.SZ)：碘普罗胺原料药获得化学原料药上市申请批准

智通财经2025-07-01

智通财经APP讯，北陆药业(300016.SZ)发布公告，近日，公司控股子公司浙江海昌药业股份有限公司(以下简称“海昌药业”)收到国家药品监督管理局核准签发的碘普罗胺《化学原料药上市申请批准通知书》。据悉，碘普罗胺(Iopromide)为对比剂碘普罗胺注射液的原料药，碘普罗胺注射液是一种非离子、水溶性、三碘化的X射线造影剂，可用于CT增强，动脉造影和静脉造影，静脉尿路造影，内窥镜逆行胰胆管造影(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548072380?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-01 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548072380","market":"fut","top_or_hot":-1,"title":"北陆药业(300016.SZ)：碘普罗胺原料药获得化学原料药上市申请批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，北陆药业(300016.SZ)发布公告，近日，公司控股子公司浙江海昌药业股份有限公司(以下简称“海昌药业”)收到国家药品监督管理局核准签发的碘普罗胺《化学原料药上市申请批准通知书》。据悉，碘普罗胺(Iopromide)为对比剂碘普罗胺注射液的原料药，碘普罗胺注射液是一种非离子、水溶性、三碘化的X射线造影剂，可用于CT增强，动脉造影和静脉造影，静脉尿路造影，内窥镜逆行胰胆管造影(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1312608.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>北陆药业(300016.SZ)：碘普罗胺原料药获得化学原料药上市申请批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n北陆药业(300016.SZ)：碘普罗胺原料药获得化学原料药上市申请批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-01 17:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1312608.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，北陆药业(300016.SZ)发布公告，近日，公司控股子公司浙江海昌药业股份有限公司(以下简称“海昌药业”)收到国家药品监督管理局核准签发的碘普罗胺《化学原料药上市申请批准通知书》。据悉，碘普罗胺(Iopromide)为对比剂碘普罗胺注射液的原料药，碘普罗胺注射液是一种非离子、水溶性、三碘化的X射线造影剂，可用于CT增强，动脉造影和静脉造影，静脉尿路造影，内窥镜逆行胰胆管造影(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1312608.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300016","symbol_name":"北陆药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1312608.html","article_id":"2548072380","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548072380","pubTimestamp":1751361963,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，北陆药业 发布公告，近日，公司控股子公司浙江海昌药业股份有限公司收到国家药品监督管理局核准签发的碘普罗胺《化学原料药上市申请批准通知书》。据悉，碘普罗胺为对比剂碘普罗胺注射液的原料药，碘普罗胺注射液是一种非离子、水溶性、三碘化的X射线造影剂，可用于CT增强，动脉造影和静脉造影，静脉尿路造影，内窥镜逆行胰胆管造影，关节腔造影和其他体腔检查等，不能在鞘内使用。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300016":"北陆药业","BK0046":"生物疫苗","BK0042":"基因检测","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"Hokuriku Pharmaceutical (300016. SZ): Iopromide API obtained approval for chemical API marketing application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300016":1},"content_text":"智通财经APP讯，北陆药业(300016.SZ)发布公告，近日，公司控股子公司浙江海昌药业股份有限公司(以下简称“海昌药业”)收到国家药品监督管理局核准签发的碘普罗胺《化学原料药上市申请批准通知书》。据悉，碘普罗胺(Iopromide)为对比剂碘普罗胺注射液的原料药，碘普罗胺注射液是一种非离子、水溶性、三碘化的X射线造影剂，可用于CT增强，动脉造影和静脉造影，静脉尿路造影，内窥镜逆行胰胆管造影(ERCP)，关节腔造影和其他体腔检查等，不能在鞘内使用。本次海昌药业碘普罗胺原料药获得《化学原料药上市申请批准通知书》，不仅将进一步丰富海昌药业原料药品种，提升其市场竞争力，推动海昌药业原料药销售业务稳步增长，也将扩大公司在对比剂领域内原料药制剂一体化的深度和广度，为公司扩大在对比剂领域的竞争优势和市场份额创造有利条件。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548072380","isCrawlerRequest":true}